Flagship Pioneering (fka Flagship Ventures), a Cambridge, MA-based life sciences venture capital firm, is seeking to raise $500m for its latest fund.
Per an SEC regulatory filing, Flagship Pioneering Fund VI, L.P. has not raised funds, yet.
The form lists Noubar Afeyan, Senior Managing Partner & CEO, as person related to the offering.
The firm, which rebranded from Flagship Ventures to Flagship Pioneering in December 2016, conceives, creates, resources and develops life sciences companies. Its institutional innovation foundry, Flagship VentureLabs, enables its team of scientific entrepreneurs to systematically evolve enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. The firm leverages corporate innovation alliances with several market leaders, including AstraZeneca, Bayer Crop Science and Nestlé Health Science.
Since its launch in 2000, Flagship has originated and fostered nearly 80 scientific ventures, resulting in approx. $20 billion in aggregate value.
The portfolio includes Agios Pharmaceuticals (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), Editas Medicine (NASDAQ: EDIT) and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies including Moderna Therapeutics, Indigo Agriculture and Axcella Health, among others.